Effects of cholinesterase inhibition on attention and working memory in Lewy body dementias
dc.contributor.author | Fallon, SJ | |
dc.contributor.author | Plant, O | |
dc.contributor.author | Tabi, YA | |
dc.contributor.author | Manohar, SG | |
dc.contributor.author | Husain, M | |
dc.date.accessioned | 2023-08-01T15:08:35Z | |
dc.date.available | 2023-08-01T15:08:35Z | |
dc.date.issued | 2023-07-01 | |
dc.identifier.issn | 2632-1297 | |
dc.identifier.issn | 2632-1297 | |
dc.identifier.other | ARTN fcad207 | |
dc.identifier.uri | https://pearl.plymouth.ac.uk/handle/10026.1/21123 | |
dc.description.abstract |
Cholinesterase inhibitors are frequently used to treat cognitive symptoms in Lewy body dementias (Parkinson’s disease dementia and Dementia with Lewy bodies). However, the selectivity of their effects remains unclear. In a novel rivastigmine-withdrawal design, Parkinson’s disease dementia and Dementia with Lewy bodies patients were tested twice: once when taking rivastigmine as usual and once when they had missed one dose. In each session, they performed a suite of tasks (sustained attention, simple short-term recall, distractor resistance and manipulating the focus of attention) which allowed us to investigate the cognitive mechanisms through which rivastigmine affects attentional control. Consistent with previous literature, rivastigmine withdrawal significantly impaired attentional efficacy (quicker response latencies without a change in accuracy). However, it had no effects on cognitive control as assessed by the ability to withhold a response (inhibitory control). Worse short-term memory performance was also observed when patients were OFF rivastigmine, but these effects were delay and load-independent, likely due to impaired visual attention. In contrast to previous studies that have examined the effects of dopamine withdrawal, cognitively complex tasks requiring control over the contents of working memory (ignoring, updating or shifting the focus of attention) were not significantly impaired by rivastigmine withdrawal. Cumulatively, these data support the conclusion cholinesterase inhibition has relatively specific and circumscribed – rather than global – effects on attention that may also affect performance on simple short-term memory tasks, but not when cognitive control over working memory is required. The results also indicate that withdrawal of a single dose of rivastigmine is sufficient to reveal these impairments, demonstrating that cholinergic withdrawal can be an informative clinical as well as an investigative tool. | |
dc.format.extent | fcad207- | |
dc.format.medium | Electronic-eCollection | |
dc.language | en | |
dc.publisher | Oxford University Press (OUP) | |
dc.subject | Lewy body dementias | |
dc.subject | sustained attention | |
dc.subject | working memory | |
dc.subject | acetylcholine | |
dc.subject | cholinesterase inhibitors | |
dc.title | Effects of cholinesterase inhibition on attention and working memory in Lewy body dementias | |
dc.type | journal-article | |
dc.type | Article | |
plymouth.author-url | https://www.ncbi.nlm.nih.gov/pubmed/37545547 | |
plymouth.issue | 4 | |
plymouth.volume | 5 | |
plymouth.publisher-url | http://dx.doi.org/10.1093/braincomms/fcad207 | |
plymouth.publication-status | Published | |
plymouth.journal | Brain Communications | |
dc.identifier.doi | 10.1093/braincomms/fcad207 | |
plymouth.organisational-group | |Plymouth | |
plymouth.organisational-group | |Plymouth|Faculty of Health | |
plymouth.organisational-group | |Plymouth|Faculty of Health|School of Psychology | |
plymouth.organisational-group | |Plymouth|REF 2021 Researchers by UoA | |
plymouth.organisational-group | |Plymouth|Users by role | |
plymouth.organisational-group | |Plymouth|Users by role|Academics | |
plymouth.organisational-group | |Plymouth|REF 2021 Researchers by UoA|UoA04 Psychology, Psychiatry and Neuroscience | |
dc.publisher.place | England | |
dcterms.dateAccepted | 2023-06-01 | |
dc.date.updated | 2023-08-01T15:08:24Z | |
dc.rights.embargodate | 2023-8-2 | |
dc.identifier.eissn | 2632-1297 | |
dc.rights.embargoperiod | forever | |
rioxxterms.versionofrecord | 10.1093/braincomms/fcad207 |